{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+First+Intervention+%283+weeks%29&page=2",
    "query": {
      "intervention": "Placebo Comparator: First Intervention (3 weeks)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 111,
    "total_pages": 12,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+First+Intervention+%283+weeks%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Comparator%3A+First+Intervention+%283+weeks%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T10:06:01.668Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03199885",
      "title": "Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Breast Adenocarcinoma",
        "Metastatic HER2-Positive Breast Carcinoma",
        "Recurrent Breast Adenocarcinoma",
        "Recurrent HER2-Positive Breast Carcinoma",
        "Stage III Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Unresectable Breast Carcinoma",
        "Unresectable HER2-Positive Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo Administration",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 190,
      "start_date": "2019-04-05",
      "completion_date": "2025-04-04",
      "has_results": true,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-08T10:06:01.668Z",
      "location_count": 662,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 506 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03199885"
    },
    {
      "nct_id": "NCT01656187",
      "title": "Attenuation of Corticosteroid Induced Hippocampal Changes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Organic Memory Impairment"
      ],
      "interventions": [
        {
          "name": "Memantine 10 mg capsule",
          "type": "DRUG"
        },
        {
          "name": "Memantine-matched Placebo capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 46,
      "start_date": "2012-01",
      "completion_date": "2017-01",
      "has_results": true,
      "last_update_posted_date": "2019-03-29",
      "last_synced_at": "2026-10-08T10:06:01.668Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01656187"
    },
    {
      "nct_id": "NCT02039115",
      "title": "Reduction in Symptomatic Esophageal Stricture Formation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Esophageal Stenosis"
      ],
      "interventions": [
        {
          "name": "prednisone",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AdventHealth",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 3,
      "start_date": "2014-03",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2017-09-08",
      "last_synced_at": "2026-10-08T10:06:01.668Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02039115"
    },
    {
      "nct_id": "NCT04199104",
      "title": "A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Lenvatinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 511,
      "start_date": "2020-02-05",
      "completion_date": "2025-03-31",
      "has_results": true,
      "last_update_posted_date": "2026-05-05",
      "last_synced_at": "2026-10-08T10:06:01.668Z",
      "location_count": 26,
      "location_summary": "Fresno, California • San Marcos, California • Aurora, Colorado + 22 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04199104"
    },
    {
      "nct_id": "NCT06853912",
      "title": "PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder (AUD)",
        "PTSD"
      ],
      "interventions": [
        {
          "name": "Psilocybin 25 mg",
          "type": "DRUG"
        },
        {
          "name": "Maltodextrin (Placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nathan Brashares Sackett",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2025-06-01",
      "completion_date": "2027-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-08T10:06:01.668Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06853912"
    },
    {
      "nct_id": "NCT01440023",
      "title": "Developing Cognitive Training for Tourette Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tourette Syndrome",
        "Chronic Tic Disorders"
      ],
      "interventions": [
        {
          "name": "Comprehensive Behavioral Intervention for Tics (CBIT)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Computerized Response Inhibition Training",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Computerized Placebo Cognitive Training",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Wisconsin, Milwaukee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "9 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "9 Years to 17 Years"
      },
      "enrollment_count": 20,
      "start_date": "2011-08",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-01-15",
      "last_synced_at": "2026-10-08T10:06:01.668Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01440023"
    },
    {
      "nct_id": "NCT03069391",
      "title": "The Interactive Physical and Cognitive Exercise System",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alzheimer Disease, Early Onset",
        "MCI",
        "Aging",
        "Mild Cognitive Impairment",
        "Neurocognitive Disorder",
        "Cognitive Impairment",
        "Cognitive Change"
      ],
      "interventions": [
        {
          "name": "physical exercise alone (PES) first",
          "type": "BEHAVIORAL"
        },
        {
          "name": "cognitive exercise alone (iCE) first",
          "type": "DEVICE"
        },
        {
          "name": "interactive Physical and Cognitive Exercise (iPACES™)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "DEVICE"
      ],
      "sponsor": "Union College, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2017-03-04",
      "completion_date": "2022-06-30",
      "has_results": false,
      "last_update_posted_date": "2020-03-31",
      "last_synced_at": "2026-10-08T10:06:01.668Z",
      "location_count": 1,
      "location_summary": "Schenectady, New York",
      "locations": [
        {
          "city": "Schenectady",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03069391"
    },
    {
      "nct_id": "NCT00663611",
      "title": "Growth Hormone Administration and the Human Immune System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Norditropin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Aging (NIA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "25 Years to 50 Years · Male only"
      },
      "enrollment_count": 66,
      "start_date": "2006-10-19",
      "completion_date": "2014-10-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-08T10:06:01.668Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00663611"
    },
    {
      "nct_id": "NCT01944046",
      "title": "Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autism Spectrum Disorders"
      ],
      "interventions": [
        {
          "name": "Double blind phase Placebo Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "double Blind Oxytocin Nasal Spray",
          "type": "DRUG"
        },
        {
          "name": "Open Label intranasal oxytocin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Linmarie Sikich",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 290,
      "start_date": "2014-08-01",
      "completion_date": "2017-11-30",
      "has_results": true,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-10-08T10:06:01.668Z",
      "location_count": 7,
      "location_summary": "Boston, Massachusetts • New York, New York • White Plains, New York + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "White Plains",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01944046"
    },
    {
      "nct_id": "NCT02616094",
      "title": "Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Alcohol Dependence"
      ],
      "interventions": [
        {
          "name": "Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1",
          "type": "DEVICE"
        },
        {
          "name": "Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 224,
      "start_date": "2015-11",
      "completion_date": "2022-06-30",
      "has_results": false,
      "last_update_posted_date": "2023-04-18",
      "last_synced_at": "2026-10-08T10:06:01.668Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02616094"
    }
  ]
}